Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Journal of Virology|June 20, 2001
Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapyA J Hance, V Lemiale, J Izopet, et al.
AIDS (London, England)|December 2, 1998
A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjectsS Staszewski, C Katlama, T Harrer, et al.
Medecine Et Maladies Infectieuses|November 10, 2018
Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in FranceP Pugliese, V Joly, M A Valantin, et al.
HIV Medicine|August 1, 2018
Interest of cytology combined with Xpert® HPV and Anyplex® II HPV28 Detection human papillomavirus (HPV) typing: differential profiles of anal and cervical HPV lesions in HIV-infected patients on antiretroviral therapyH Nassereddine, C Charpentier, M Bucau, et al.
HIV Clinical Trials|February 3, 2006
Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS studyR Landman, D Descamps, G Peytavin, et al.
HIV Medicine|February 10, 2009
Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136)P Yeni, A Lamarca, D Berger, et al.
Lancet (London, England)|July 25, 2006
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial, P Yeni, D A Cooper, et al.
Antimicrobial Agents and Chemotherapy|May 5, 2010
Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patientsLucile Larrouy, C Chazallon, R Landman, et al.
Open Forum Infectious Diseases|August 11, 2022
Treatment With a Three-Drug Regimen for Pulmonary Tuberculosis Based on Rapid Molecular Detection of Isoniazid Resistance: A Noninferiority Randomized Trial (FAST-TB)N De Castro, F Mechaï, D Bachelet, et al.
Antiviral Therapy|February 22, 2000
Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over studyB Masquelier, D Descamps, I Carrière, et al.
Pageof 10